VEGFA and renal cell carcinoma: Under the first category, bevacizumab (Avastin) is an anti-VEGFA ligand inhibitor approved by the FDA to treat metastatic CRC and renal cell carcinomas (RCC) in combination with traditional therapeutics (Cardones and Banez, 2006).